NeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System for Idiopathic Generalized Epilepsy

NEXT STORY
NeuroPace Reports Third Quarter 2021 Financial Results
PREV STORY
ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Anti-VEGF Antibodies Market to 2022: Roche, Novartis, Sanofi, Regeneron, Bayer & AstraZeneca Dominate the $100 Billion Market

Dublin, Aug. 09, 2018 (GLOBE NEWSWIRE) -- The "Anti-VEGF Antibodies: Global Technology Assessment, Market ...

author_avatar
NASDAQ Market News

Generex Biotechnology Announces That FDA has Accepted the Pre-IND Briefing Package for the Company’s Ii-Key-SARS-CoV-2 Vaccine and Will Provide a Written Response by August 24, 2020

author_avatar
NASDAQ Market News

First patient treated with C-RAD’s cutting-edge positioning system at the Cancer Care Center Negrar-Verona, Italy

author_avatar
NASDAQ Market News